Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

Healthcare: What Was Biogen Thinking?

  • Broadcast in Finance
  • 0 comments
Industry Focus

Industry Focus

×  

Follow This Show

If you liked this show, you should follow Industry Focus.
h:899941
s:10719113
archived

Biogen misses out on a huge deal that Novartis completed with AveXis. Plus, Incyte's phase 3 implosion, and what it means for immuno-oncology more broadly.

Comments

 comments